Clinical and Molecular Retrovirology Section
Established in 1989
Irini Sereti, M.D., Ph.D.
Chief, Laboratory of Immunoregulation
Senior Investigator, Chief HIV Pathogenesis Section
Acting Chief, Clinical and Molecular Retrovirology Section
Acting Chief, Immunopathogenesis Section
Specialty(s): Infectious Disease, Internal Medicine Provides direct clinical care to patients at NIH Clinical Center
Major Areas of Research
- Pathogenesis of HIV infection emphasizing mechanisms of immunodeficiency
- Immunologic approaches to therapy for HIV infection
- Emerging Infectious Diseases (COVID-19; Ebola)
Program Description
The early work of the Clinical and Molecular Retrovirology Section involved studies aimed at dissecting the normal immunoregulatory mechanisms that control the human immune response to specific antigen challenges. When the AIDS epidemic emerged, H. Clifford Lane, M.D., became one of the first investigators to study immunopathogenic mechanisms of HIV disease, ultimately making seminal observations that helped establish the field of HIV immunopathogenesis.
The laboratory has used investigational therapeutic interventions to further the understanding of HIV pathogenesis and pioneered the strategies of immunologically compatible bone marrow transplantation and the adoptive transfer of lymphocytes. The lab has also examined the roles of cytokines in treating patients with HIV infection.
Biography
Education
Ph.D., University of Amsterdam - Netherlands
M.D., National Kapodistrian University of Athens in Greece
M.H.S., Duke University
Dr. Sereti is the Chief of the HIV Pathogenesis Section in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases (NIAID). She received her medical degree at the National Kapodistrian University of Athens in Greece and did her internal medicine residency and chief residency at Northwestern University in Chicago. She completed an M.H.S. from Duke University and her infectious diseases fellowship at NIAID and stayed as a clinical investigator receiving tenure in 2015.
Selected Publications
Polizzotto, M., Nordwall, J., Babiker, A.G., Phillips, A., Vock, D.M., Eriobu, N., Khwaghe, V., Paredes, R.,Mateu, L.,Ramachandruni, S., [76 others], Lane, H.C (2022). Hyperimmune Immunoglobulin for Hospitalized Patients With COVID-19. The Lancet 399:530-540, 2022.
Higgs ES, Gayedyu-Dennis D, Fischer Ii WA, Nason M, Reilly C, Beavogui AH, Aboulhab J, Nordwall J, Lobbo P, Wachekwa I, Cao H, Cihlar T, Hensley L, Lane HC. PREVAIL IV: A Randomized, Double-Blind, 2-Phase, Phase 2 Trial of Remdesivir vs Placebo for Reduction of Ebola Virus RNA in the Semen of Male Survivors. Clin Infect Dis. 2021 Nov 16;73(10):1849-1856.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020 Nov 5;383(19):1813-1826.
Imamichi H, Smith M, Adelsberger JW, Izumi T, Scrimieri F, Sherman BT, Rehm CA, Imamichi T, Pau A, Catalfamo M, Fauci AS, Lane HC. Defective HIV-1 proviruses produce viral proteins. Proc Natl Acad Sci U S A. 2020 Feb 18;117(7):3704-3710.
Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, Ali R, Coulibaly S, Levine AC, Grais R, Diaz J, Lane HC, Muyembe-Tamfum JJ; PALM Writing Group, Sivahera B, Camara M, Kojan R, Walker R, Dighero-Kemp B, Cao H, Mukumbayi P, Mbala-Kingebeni P, Ahuka S, Albert S, Bonnett T, Crozier I, Duvenhage M, Proffitt C, Teitelbaum M, Moench T, Aboulhab J, Barrett K, Cahill K, Cone K, Eckes R, Hensley L, Herpin B, Higgs E, Ledgerwood J, Pierson J, Smolskis M, Sow Y, Tierney J, Sivapalasingam S, Holman W, Gettinger N, Vallée D, Nordwall J; PALM Consortium Study Team. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med. 2019 Dec 12;381(24):2293-2303.
Di Mascio M, Srinivasula S, Kim I, Duralde G, St Claire A, DeGrange P, St Claire M, Reimann KA, Gabriel EE, Carrasquillo J, Reba RC, Paik C, Lane HC. Total body CD4+ T cell dynamics in treated and untreated SIV infection revealed by in vivo imaging. JCI Insight. 2018 Jul 12;3(13):e97880.
Research Group
- Michael Sneller – Medical Officer
- Hiromi Imamichi– Staff Scientist
- Marta Catalfamo – Guest Researcher
- Vishakha Thaker– Biologist
- Mindy Smith – Biologist
- Hui Chen – Visiting Fellow
- Bruktawit Goshu – Post Bac IRTA
- Tracey Zhai – Post Bac IRTA
- Cecile Le Saout – Special Volunteer
- Francesca Scrimieri - Special Volunteer
- Steven Zeichner – Special Volunteer
Affiliations
INSIGHT (global), INA-RESPOND (Indonesia), La RED (Mexico), PREVAIL (Liberia), UCRC (Mali), PREGUI (Guinea), PALM (DRC)
Training Programs
Patents
- Lane HC, Kovacs JA, Fauci AS, inventors; The United States of America as represented by the Department of Health and Human Services, assignee. Immunologic enhancement with intermittent interleukin-2 therapy. United States patent US 6,548,055. 15 Apr 2003.
- Lane HC, Kovacs JA, Fauci AS, inventors; The United States of America as represented by the Department of Health and Human Services, assignee. Immunologic enhancement with intermittent interleukin-2 therapy. United States patent US 6,190,656. 20 Feb 2001.
- Lane HC, Kovacs JA, Fauci AS, inventors; The United States of America as represented by the Department of Health and Human Services, assignee. Immunologic enhancement with intermittent interleukin-2 therapy. United States patent US 5,696,079. 9 Dec 1997.
- Lane HC, Kovacs JA, inventors; The United States of America as represented by the Department of Health and Human Services, assignee. Immunologic enhancement with intermittent interleukin-2 therapy. United States patent US 5,419,900. 30 May 1995.
Visit the U.S. Patent and Trademark Office for a complete patent listing.